Therefore, the results obtained in this study indicate the main interactions that occur between the inhibitors studied and the biological targets and may help the proposition of new potential dual inhibitors of HER-2 and EGFR, candidates to treat breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.